KLOW for Gut Health: What the Evidence Shows
What human and animal studies show about KLOW for gut health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- from an ingredient's studies
- Human studies
- None found
- with an outcome for gut health, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 7
- with an outcome for gut health, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 7
- with an outcome for gut health
Evidence for gut health
Each row is an outcome related to gut health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here. No study has tested KLOW itself; rows are for each ingredient.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| GHK-Cu: Colitis severity and mucosal repair | GHK-Cu reduced weight loss, disease activity and colonic inflammatory damage and promoted mucosal repair in DSS colitis mice. | Animal · mouse (plus mouse cell co-culture) (not a human result) | Frontiers in pharmacology 2025, PMID 40672369 |
| BPC-157: Ischemic colon blood supply | In rats with ischemic colitis, BPC 157 restored blood supply to the injured colon and activated collateral vessels. | Animal · rat (not a human result) | World journal of gastroenterology 2017, PMID 29358856 |
| BPC-157: Colitis and anastomosis healing | Control rats did not heal; BPC 157 induced healing of both cysteamine colitis and colon-colon anastomosis. | Animal · rat (not a human result) | Journal of physiology and pharmacology 2013, PMID 24304574 |
| BPC-157: Fistula healing | BPC 157 given by injection or by mouth accelerated healing of the colon and skin defects and closed the fistula. | Animal · rat (not a human result) | Journal of pharmacological sciences 2008, PMID 18818478 |
| KPV: DSS colitis recovery | KPV-treated mice recovered earlier and regained more body weight in DSS colitis. | Animal · mouse (not a human result) | Inflammatory bowel diseases 2008, PMID 18092346 |
| KPV: Survival in MC1R-nonfunctional mice | KPV treatment rescued all treated MC1R-nonfunctional mice from death during DSS colitis. | Animal · mouse (not a human result) | Inflammatory bowel diseases 2008, PMID 18092346 |
| KPV: Colitis incidence (oral KPV) | Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice and lowered inflammatory cytokine expression. | Animal · mouse (plus human intestinal epithelial and T cell lines) (not a human result) | Gastroenterology 2008, PMID 18061177 |
| BPC-157: Gastric ulcer | BPC 157 given intramuscularly or intragastrically reduced ulcer area and accelerated ulcer healing in rats; intramuscular dosing was better than intragastric. | Animal · rat (not a human result) | World journal of gastroenterology 2004, PMID 15052688 |
KLOW and gut health are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Digestive disorders as MedlinePlus frames them
MedlinePlus lists the organs a digestive disorder can involve.[8]
Gut studies for the blend's components, all in animals
The GHK-Cu component was tested in mice given DSS to cause ulcerative colitis, where it eased weight loss and promoted mucosal repair.[1]
The KPV component showed anti-inflammatory effects in 2 mouse models of colitis.[5]
KPV given by mouth to mice reduced the incidence of two chemically induced colitis models.[6]
The BPC-157 component restored blood supply to an injured colon segment in rats.[2]
BPC-157 in rats also reduced gastric ulcers, with the intramuscular route stronger than the intragastric one.[7]
The four components together returned 0 PubMed records on 2 Oct 2026, so the blend itself has no gut study.
Calculated from search GHK-Cu terms AND BPC-157 terms AND (TB-500 OR thymosin beta-4 terms) AND KPV terms; date 2026-10-02; count 0; page topic gut health; source our combinations data ghk-cu__klow. Formula: records matching all four components = count = 0
Other peptides people research for gut health
All peptides for gut health, comparedCommon questions
Does KLOW help with gut health?
The strongest study we summarise for gut health is animal evidence, for an ingredient rather than the blend, across 7 studies with an outcome for gut health. That is not proof it works in people.
Is KLOW approved for gut health?
No. KLOW is not FDA approved for any use, including gut health.
What is the best peptide for gut health?
There is no single answer. Our gut health overview compares each candidate by evidence grade and legal status rather than by popularity.
Is KLOW good for gut health?
Every gut result listed is in mice or rats and tests one component at a time.[3]
More on KLOW
Sources
- 1Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.Frontiers in pharmacology · 2025PMID 40672369Accessed 2 Oct 2026
- 2Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights.World journal of gastroenterology · 2017PMID 29358856Accessed 2 Oct 2026
- 3Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2013PMID 24304574Accessed 2 Oct 2026
- 4Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.Journal of pharmacological sciences · 2008PMID 18818478Accessed 2 Oct 2026
- 5Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 6PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
- 7Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.World journal of gastroenterology · 2004PMID 15052688Accessed 2 Oct 2026
- 8medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
Found an error? Report a correction.